SCHEMBL2086824

SCHEMBL2086824

CON(C)C(=O)c1cn2c(C)c(Br)ccc2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.36
KDM4E B2RXH2 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
RAB9A P51151 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CLK1 P49759 1/20 0.33
DYRK1A Q13627 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
TRPM8 Q7Z2W7 1/20 0.31
HPGD P15428 2/20 0.30
HSD17B10 Q99714 2/20 0.30
LMNA P02545 1/20 0.30
ALB P02768 1/20 0.30
CYP3A4 P08684 1/20 0.30
CHRM1 P11229 1/20 0.30
GABRA1 P14867 1/20 0.30
GABRB1 P18505 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2086528 0.79 PTGS1 (0.41) GAAKDM4ERAB9AALDH1A1SMN1; SMN2
SCHEMBL2086819 0.78 GAA (0.59) GAAKDM4EMEN1KMT2ARAB9A
SCHEMBL117177 0.76 GAA (0.63) GAAKDM4EKMT2ARAB9AGABRA2
SCHEMBL1500384 0.76 APP (0.47) KDM4EMEN1KMT2ARAB9AALDH1A1
SCHEMBL3769993 0.75 APP (0.44) KDM4EMEN1KMT2ARAB9AALDH1A1
SCHEMBL4247423 0.73
SCHEMBL17810146 0.71 ALDH1A1 (0.39) GAAKDM4EMEN1KMT2ARAB9A
SCHEMBL2086662 0.70 HRH4 (0.52) KDM4ERAB9AALDH1A1SMN1; SMN2TDP1
SCHEMBL3367638 0.70 RAB9A (0.53) GAAKMT2ARAB9ASMN1; SMN2LMNA
SCHEMBL12306368 0.69 KDM4E (0.35) KDM4EMEN1KMT2ARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902219-B2 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-08 US disclosed
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF NR4A2, NR4A3, NCOR1 GAA 4741/4885KDM4E 2764/4885MEN1 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.